BSX
Boston Scientific Corp.
$50.38
장중 · Vol 475.5K · 52주 $42.20–$109.50 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $46.64 · Aug 31, 2026
BSX 가격 추세
종가
$46.64
시가
$46.85
고가
$46.69
저가
$46.10
30초 브리핑
BSX 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 12%
연중 저점권입니다. 반등 신호보다 하락 원인을 먼저 확인하세요.
Forward P/E 14.1배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 2.8배
평소보다 거래가 활발해 가격 움직임의 확인 강도가 높습니다.
2026-10-28
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
BSX 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
300 Boston Scientific Way · Marlborough, MA, United States · 직원 59,000명
시가총액
$70.00B
Trailing P/E
18.9
최근 12개월 이익 기준
Forward P/E
14.1
이익 증가 기대 반영
EPS (TTM)
$2.55
배당 수익률
—
배당성향
0.0%
베타
0.57
시장보다 방어적
ROE
15.3%
P/B
2.80
EV/EBITDA
14.0
52주 범위
$42.20 – $109.50
현재 위치 12%
거래량
35.98M
20일 평균 12.98M · 2.8배
애널리스트 의견
매수 84%
총 31명 · 0m
DITM LEAPS Analysis
BSX 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX280121C00025000 | 1/21/28 · 1.4Y | $25.00 | $26.30 | 1.7x | 0.9043 | 11.4% | 6.84% | 67.24% | 162 | 82.09 | |
| BSX270917C00025000 | 9/17/27 · 1.0Y | $25.00 | $25.35 | 1.7x | 0.9154 | 8.1% | 9.07% | 66.86% | 2 | 79.76 | |
| BSX270917C00030000 | 9/17/27 · 1.0Y | $30.00 | $20.95 | 2.0x | 0.8806 | 12.7% | 12.89% | 58.13% | 20 | 76.73 | |
| BSX280121C00030000 | 1/21/28 · 1.4Y | $30.00 | $22.40 | 1.9x | 0.8655 | 18.3% | 10.71% | 61.52% | 587 | 76.06 | |
| BSX280121C00035000 | 1/21/28 · 1.4Y | $35.00 | $18.70 | 2.1x | 0.8188 | 28.9% | 9.63% | 56.42% | 810 | 68.13 | |
| BSX270917C00035000 | 9/17/27 · 1.0Y | $35.00 | $17.45 | 2.3x | 0.8239 | 23.8% | 17.77% | 56.10% | 9 | 64.12 | |
| BSX280121C00040000 | 1/21/28 · 1.4Y | $40.00 | $15.40 | 2.4x | 0.7626 | 46.1% | 7.79% | 52.67% | 1,499 | 56.69 | |
| BSX270917C00040000 | 9/17/27 · 1.0Y | $40.00 | $14.20 | 2.6x | 0.7594 | 41.5% | 12.68% | 53.39% | 42 | 53.34 |
재무제표
BSX 연간 손익·현금흐름·재무상태
매출 성장률
+19.9%
최근 연간 YoY
EPS 성장률
+55.2%
최근 연간 YoY
영업이익률
19.8%
최근 연간
FCF 마진
17.0%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $20.07B+19.9% | $16.75B+17.6% | $14.24B+12.3% | $12.68B |
| 매출총이익 | $13.85B+20.6% | $11.49B+16.1% | $9.89B+13.4% | $8.73B |
| 영업이익 | $3.97B+32.3% | $3.00B+24.2% | $2.42B+18.8% | $2.03B |
| 순이익 | $2.90B+56.3% | $1.85B+16.4% | $1.59B+128.2% | $698.00M |
| 희석 EPS | $1.94+55.2% | $1.25+16.8% | $1.07+137.8% | $0.45 |
| EBITDA | $5.10B+32.3% | $3.86B+11.9% | $3.45B+25.4% | $2.75B |
| 영업현금흐름 | $4.53B+32.0% | $3.44B+37.2% | $2.50B+64.0% | $1.53B |
| 잉여현금흐름 | $3.40B+43.9% | $2.37B+38.9% | $1.70B+86.3% | $914.00M |
| 총자산 | $43.67B+10.9% | $39.40B+12.1% | $35.14B+8.2% | $32.47B |
| 총부채 | $11.44B+6.4% | $10.75B+13.2% | $9.49B+2.3% | $9.28B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
BSX 실적·배당 일정
매출 하단
$5.20B
EPS 하단
$0.80
매출 상단
$5.30B
실적 발표일
2026-10-28
D-57
EPS 상단
$0.84
매출 컨센서스
$5.26B
EPS 컨센서스
$0.81
뉴스
BSX 관련 최신 기사
제품·기술The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.
Trefis · Sep 1, 2026
일반Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Zacks · Aug 31, 2026
- 실적
S&P 500 Posts Slight Weekly Gain as Tech Earnings Top Expectations
The Standard & Poor's 500 index edged up 0.5% this week amid stronger-than-expected quarterly report
MT Newswires · Aug 28, 2026
실적Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · Aug 28, 2026
- 제품·기술
Boston Scientific says cyberattack has disrupted product manufacturing
The attack has affected the company’s ability to manufacture products and to process and ship customers’ orders, and there is still no timeline for restoration.
MedTech Dive · Aug 28, 2026
- 제품·기술
Abbott wins CE mark for new LAA closure device
Abbott is aiming to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to reduce stroke risk.
MedTech Dive · Aug 28, 2026
일반New Strong Sell Stocks for August 28th
AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.
Zacks · Aug 28, 2026
제품·기술Has BSX Stock Fallen Far Enough To Buy?
U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.
Trefis · Aug 27, 2026
제품·기술3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.
StockStory · Aug 27, 2026
일반Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
Zacks · Aug 27, 2026
홀더
BSX 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
94.9%
기관 보유 (유동주식)
95.2%
내부자 보유
0.3%
기관 수
2,198
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 129.68M | $6.26B | 8.9% | -1.6% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 97.09M | $4.69B | 6.7% | 0.7% | Jun 30, 2026 |
| State Street Corporation | 70.11M | $3.39B | 4.8% | 3.1% | Jun 30, 2026 |
| Primecap Management Company | 50.52M | $2.44B | 3.5% | 55.3% | Jun 30, 2026 |
| FMR, LLC | 45.70M | $2.21B | 3.1% | -38.4% | Jun 30, 2026 |
| Geode Capital Management, LLC | 33.44M | $1.62B | 2.3% | 0.5% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 29.79M | $1.44B | 2.1% | -0.0% | Jun 30, 2026 |
| Shaw D.E. & Co., Inc. | 25.46M | $1.23B | 1.8% | 4.7% | Jun 30, 2026 |
| Massachusetts Financial Services Co. | 24.86M | $1.20B | 1.7% | 126.1% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 23.91M | $1.15B | 1.7% | -28.3% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.